May 13 |
AC Immune rockets 47% on Alzheimer's therapy deal with Takeda
|
May 13 |
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
|
May 13 |
Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate
|
May 13 |
AC Immune GAAP EPS of -$0.18 misses by $0.03
|
May 13 |
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
|
May 13 |
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
|
Mar 15 |
Further weakness as AC Immune (NASDAQ:ACIU) drops 12% this week, taking three-year losses to 58%
|
Jan 22 |
Roche ends AC Immune partnership for Alzheimer’s drugs
|
Jan 22 |
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
|
Jan 18 |
AC Immune (ACIU) is a Great Momentum Stock: Should You Buy?
|